Skip to main content
Equibles
MNPR logo

MNPR · Monopar Therapeutics · Investor Relations

Track MNPR — free

Use MNPR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MNPR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$71.42 +4.20 (+6.25%) At close · Nov 6
Russell 2000 member Rebalance outlook locked
Market Cap
$479.38M
Shares
6.71M
Volume · Nov 6 94.21K Avg daily vol (3M) 164.19K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-08 19:15 UTC American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® 2026 Conference
2026-11-09 00:00 UTC American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026 Event

Recent news

Date Headline
2026-11-02 Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
2026-08-12 Monopar Therapeutics Reports Second Quarter 2026
2026-07-22 Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
2026-06-30 Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
2026-06-26 Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
2026-05-19 Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
2026-05-14 Monopar Therapeutics Reports First Quarter 2026
2026-04-20 Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
2026-03-27 Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
2026-03-02 Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
2025-11-13 Monopar Therapeutics Reports Third Quarter 2025
2025-11-10 Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

Past events

Date Event Type
2026-11-05 American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® 2026 Conference
2026-06-30 12th Congress of the European Academy of Neurology (EAN 2026) Event
2026-06-22 2026 Annual Meeting of Stockholders Shareholder meeting
2026-05-30 EASL Congress 2026 Event

Source: https://ir.monopartx.com/

Key facts CIK 1645469 CUSIP 61023L207 13F (30d) 28 filings 24 filers Visit website Investor relations